Comparative Pharmacology
Head-to-head clinical analysis: GUAIFENESIN versus GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GUAIFENESIN versus GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE.
GUAIFENESIN vs GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.
Guaifenesin is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity. Dextromethorphan is a centrally acting cough suppressant that binds to NMDA receptors and sigma-1 receptors, elevating the cough threshold.
Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.
For adults and children ≥12 years: 10 mL (200 mg guaifenesin, 20 mg dextromethorphan) orally every 4 hours, not to exceed 60 mL (1200 mg guaifenesin, 120 mg dextromethorphan) per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours; clinical context: requires dosing every 4-6 hours for sustained mucolytic effect
Guaifenesin: 1-2 hours; Dextromethorphan: 3-6 hours (extensive metabolizers), 18-24 hours (poor metabolizers due to CYP2D6 polymorphism).
Renal: ~95% (primarily as unchanged drug and glucuronide conjugate); biliary/fecal: minimal (<5%)
Guaifenesin: ~60% renal (metabolites), ~35% fecal; Dextromethorphan: ~70% renal (parent and metabolites, 45% as unchanged dextrorphan), ~20% biliary/fecal.
Category C
Category C
Expectorant
Expectorant/Antitussive Combination